Mendus (Q4 review): CML a New Value Driver - Redeye

Redeye comments on Mendus’ Q4 report. We have updated our valuation scenarios and present a new base case. We still view AML as the most valuable indication. However, in the long term, as more clinical data become available, CML could take the lead with multi-blockbuster potential. We discuss recent developments in the CML space.

Länk till analysen i sin helhet: https://www.redeye.se/research/1150785/mendus-q4-review-cml-a-new-value-driver?utm_source=finwire&utm_medium=RSS